SynthesisScientific reports2026
Clinical characteristics, imaging features, and treatment outcomes of macular telangiectasia type 2: a comprehensive meta-analysis.
Synthesis in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cognitive Physiology in Healthy Young Adults: Links to Ciliary Neurotrophic Factor and Retinal Biomarkers.Diagnostics (Basel, Switzerland) · 2026Article
- Is Macular Telangiectasia Type 2 Associated with Hearing Loss and Cochlear Dysfunction? A Prospective Case-Control Study.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Macular telangiectasia type 2 (MacTel type 2) is a rare bilateral retinal neurodegenerative disorder characterized by parafoveal capillary dilation and progressive photoreceptor loss, potentially leading to visual impairment. Despite increasing recognition, uncertainties remain regarding its diagnosis and optimal management. This study aimed to comprehensively summarize the demographics, clinical characteristics, management, and prognosis of MacTel type 2. PubMed, EMBASE, and Ovid were searched from inception to March 2024. Statistical analyses were performed with R 3.6.3. A total of 205 studies comprising 11,045 patients were included. MacTel type 2 showed female- predominance (male ratio: 38%) and was frequently associated with metabolic comorbidities, including hypertension (41%), diabetes mellitus (35%), and dyslipidemia (33%). More than half (55%) of patients had a BCVA better than 20/40, and 12% presented with proliferative disease. In the proliferative stage, anti-VEGF therapy resulted in visual improvement in 59% of patients, compared with 7% under observation. In the non-proliferative stage, anti-VEGF therapy and observation yielded improvement rates of 58% and 31%, respectively. Among patients with full-thickness macular hole, pars plana vitrectomy (PPV) with internal limiting membrane (ILM) flap demonstrated higher MH closure rates (92% vs. 44%) and better visual outcomes (60% vs. 45%) than PPV with ILM peeling. MacTel type 2 mainly affects females, usually associated with metabolic comorbidities, and generally causes mild visual impairment. Anti-VEGF therapy may offer greater benefit over observation in the proliferative stage, whereas its effectiveness in non-proliferative disease remains uncertain. For patients complicated with full-thickness macular holes, PPV assisted with an ILM flap provides superior anatomical and visual outcomes compared with ILM peeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.